Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06832592 | Supportive Care Needs of Bronchial Cancer Patients in Active Treatment: A Descriptive Study in Outpatient Oncology | completed | — | 100 | L'hôpital Nord-Ouest - Villefranche Villefranche sur SaôneOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT04364620 | AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) | completed | Phase 2 | 35 | Alethia BiotherapeuticsINDUSTRY | 2 | Apr 6, 2025 |
| clinicaltrials |
| NCT03197467 | Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer(NEOMUN) | completed | Phase 2 | 30 | AIO-Studien-gGmbHOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT04735068 | Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer | completed | Phase 2 | 9 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05834348 | A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.(DELINOR) | completed | — | 5,279 | PfizerINDUSTRY | 1 | Mar 30, 2025 | clinicaltrials |
| NCT05298176 | Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors(COMBINATION) | completed | Phase 2 | 5 | Amsterdam UMC, location VUmcOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT03389399 | Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases | completed | — | 18 | University of Colorado, DenverOTHER | 2 | Mar 25, 2025 | clinicaltrials |
| NCT03631784 | A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)(KEYNOTE-799) | completed | Phase 2 | 216 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 25, 2025 | clinicaltrials |
| NCT02582125 | ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 53 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | completed | Phase 1 | 64 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04003246 | Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 10 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05337163 | A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China | completed | — | 1,564 | Creative Biosciences (Guangzhou) Co., Ltd.INDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02437136 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | completed | Phase 1 / Phase 2 | 191 | Syndax PharmaceuticalsINDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment(SPRINT) | completed | Phase 1 / Phase 2 | 126 | Karyopharm Therapeutics IncINDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | completed | Phase 2 | 139 | EpicentRx, Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT03676192 | To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 689 | CelltrionINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05058560 | Tislelizumab in Addition to BACE in Patients with NSCLC | completed | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05505825 | A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | AkesoINDUSTRY | 2 | Mar 12, 2025 | clinicaltrials |
| NCT05619744 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | completed | Phase 1 | 41 | Hoffmann-La RocheINDUSTRY | 5 | Mar 10, 2025 | clinicaltrials |
| NCT00446225 | Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR(EURTAC) | completed | Phase 3 | 174 | Spanish Lung Cancer GroupOTHER | 3 | Mar 5, 2025 | clinicaltrials |
| NCT06495008 | Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy(TasteSPICIER) | completed | — | 101 | University Medical Center GroningenOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT03812549 | Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients | completed | Phase 1 | 29 | Sichuan UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT02535338 | Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04880863 | NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC(NT-NAP-102-1) | completed | Phase 2 | 38 | NeoTX Therapeutics Ltd.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04005716 | Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer | completed | Phase 3 | 457 | BeiGeneINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04206787 | The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer | completed | — | 72 | Boehringer IngelheimINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT03543683 | Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC | completed | Phase 2 | 115 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT02424617 | A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 40 | BerGenBio ASAINDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04997382 | Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC(CLASSIC5) | completed | Phase 2 | 112 | Hunan Province Tumor HospitalOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06438367 | TGRX-326 Pharmacokinetic Mass Balance | completed | Phase 1 | 6 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT02597946 | Afatinib in NSCLC With HER2 Mutation | completed | Phase 2 | 18 | Boehringer IngelheimINDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT03088813 | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer(RESILIENT) | completed | Phase 3 | 491 | IpsenINDUSTRY | 18 | Feb 19, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04023812 | Stage III NSCLC RWE in Chinese Patients | completed | — | 500 | AstraZenecaINDUSTRY | 1 | Feb 18, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT00708448 | Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients | completed | Phase 1 | 26 | University of UtahOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03669523 | Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)(DENIVOS) | completed | Phase 2 | 82 | Centre Hospitalier Annecy GenevoisOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT01346540 | A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology. | completed | Phase 1 | 16 | Boehringer IngelheimINDUSTRY | 4 | Feb 12, 2025 | clinicaltrials |
| NCT02300298 | Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy | completed | Phase 1 | 10 | Boehringer IngelheimINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT03414814 | Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation | completed | Phase 2 | 15 | Seoul National University HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02733159 | Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2(PePS2) | completed | Phase 2 | 62 | University of BirminghamOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03358875 | Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)(RATIONALE-303) | completed | Phase 3 | 805 | BeiGeneINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT01828112 | LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | completed | Phase 3 | 231 | Novartis PharmaceuticalsINDUSTRY | 20 | Feb 7, 2025 | clinicaltrials |
| NCT02349412 | Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers | completed | Phase 3 | 405 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03532880 | A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer | completed | Phase 1 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05021328 | Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC | completed | Phase 1 | 13 | Hubei Cancer HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Apr 8, 2025source: clinicaltrials